Care Delivery
Transforming Psychedelic Care Delivery
Enabling convenient and affordable access to the therapeutic potential of psychedelics requires care delivery innovation. Andala, an Eleusis subsidiary, and affiliated physician practices, are opening clinics to provide “in-network” access to psychiatric drug therapies that require specialized care delivery.
Enabling convenient and affordable access to the therapeutic potential of psychedelics requires care delivery innovation. Andala, an Eleusis subsidiary, and affiliated physician practices, are opening clinics to provide “in-network” access to psychiatric drug therapies that require specialized care delivery.
Approach
Medicine for Living
At Eleusis, we are dedicated to unlocking the full therapeutic potential of psychedelics. Founded in 2013, our company is the leading scientific platform for the clinical evolution of psychedelics into modern medicines. Guided by world-class researchers in the field, as well as care delivery experts, we have a unique Design, Develop and Deliver approach that combines lab and healthcare capabilities in order to develop treatment options for a wide variety of diseases.
At Eleusis, we are dedicated to unlocking the full therapeutic potential of psychedelics. Founded in 2013, our company is the leading scientific platform for the clinical evolution of psychedelics into modern medicines. Guided by world-class researchers in the field, as well as care delivery experts, we have a unique Design, Develop and Deliver approach that combines lab and healthcare capabilities in order to develop treatment options for a wide variety of diseases.
Science
Striving to Unlock Psilocybin’s Breakthrough Potential
Psilocybin is an investigational drug that we believe could transform the treatment of depression. To fully realize the potential of psilocybin, however, we believe a new approach to its formulation is required - an approach targeting a consistent, controllable, and practical delivery of psilocybin’s active ingredient that could make it a mainstream treatment option for depression covered by insurance.
Psilocybin is an investigational drug that we believe could transform the treatment of depression. To fully realize the potential of psilocybin, however, we believe a new approach to its formulation is required - an approach targeting a consistent, controllable, and practical delivery of psilocybin’s active ingredient that could make it a mainstream treatment option for depression covered by insurance.
Care Delivery
Transforming Psychedelic Care Delivery
Enabling convenient and affordable access to the therapeutic potential of psychedelics requires care delivery innovation. Andala, an Eleusis subsidiary, and affiliated physician practices, are opening clinics to provide “in-network” access to psychiatric drug therapies that require specialized care delivery.
Enabling convenient and affordable access to the therapeutic potential of psychedelics requires care delivery innovation. Andala, an Eleusis subsidiary, and affiliated physician practices, are opening clinics to provide “in-network” access to psychiatric drug therapies that require specialized care delivery.
Approach
Medicine for Living
At Eleusis, we are dedicated to unlocking the full therapeutic potential of psychedelics. Founded in 2013, our company is the leading scientific platform for the clinical evolution of psychedelics into modern medicines. Guided by world-class researchers in the field, as well as care delivery experts, we have a unique Design, Develop and Deliver approach that combines lab and healthcare capabilities in order to develop treatment options for a wide variety of diseases.
At Eleusis, we are dedicated to unlocking the full therapeutic potential of psychedelics. Founded in 2013, our company is the leading scientific platform for the clinical evolution of psychedelics into modern medicines. Guided by world-class researchers in the field, as well as care delivery experts, we have a unique Design, Develop and Deliver approach that combines lab and healthcare capabilities in order to develop treatment options for a wide variety of diseases.
Science
Striving to Unlock Psilocybin’s Breakthrough Potential
Psilocybin is an investigational drug that we believe could transform the treatment of depression. To fully realize the potential of psilocybin, however, we believe a new approach to its formulation is required - an approach targeting a consistent, controllable, and practical delivery of psilocybin’s active ingredient that could make it a mainstream treatment option for depression covered by insurance.
Psilocybin is an investigational drug that we believe could transform the treatment of depression. To fully realize the potential of psilocybin, however, we believe a new approach to its formulation is required - an approach targeting a consistent, controllable, and practical delivery of psilocybin’s active ingredient that could make it a mainstream treatment option for depression covered by insurance.
Care Delivery
Transforming Psychedelic Care Delivery
Enabling convenient and affordable access to the therapeutic potential of psychedelics requires care delivery innovation. Andala, an Eleusis subsidiary, and affiliated physician practices, are opening clinics to provide “in-network” access to psychiatric drug therapies that require specialized care delivery.
Enabling convenient and affordable access to the therapeutic potential of psychedelics requires care delivery innovation. Andala, an Eleusis subsidiary, and affiliated physician practices, are opening clinics to provide “in-network” access to psychiatric drug therapies that require specialized care delivery.